Announced Fri, 15 May · 17:31 IST

Gujarat Kidney And Super Speciality Limited has shared Monitoring Agency Report for Quarter ended on 31.03.2026

GKSL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+5.1%1-day move
₹136.99
prior close
₹140.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.5-2.1-2.2-1.4+5.1+2.2+1.5+4.5+2.7-0.9-5.5-6.3-7.3
Up moveDown movePending
AI summary

Gujarat Kidney and Super Speciality Limited submitted its second Monitoring Agency Report by Brickwork Ratings for the quarter ended March 31, 2026. The company raised ₹250.80 crore through an IPO in December 2025. As of March 31, 2026, ₹100.15 crore (40%) has been utilized, leaving ₹150.65 crore unutilized. Three acquisitions have been completed: Parekhs Hospital (₹77 crore), Ashwini Medical Centre (₹12.40 crore), and additional stake in subsidiary Harmony Medicare (₹10.78 crore). ₹50.04 crore was deployed during the quarter, primarily for general corporate purposes (₹24.78 crore) and issue expenses (₹5.25 crore). Setting up of new Vadodara hospital is ongoing with ₹4.95 crore utilized out of ₹30.09 crore planned. Robotics equipment purchase remains completely unutilized at ₹6.83 crore.

Likely market impact

The report shows moderate utilization of IPO proceeds with no deviations from stated objects. Unutilized funds of ₹150.65 crore are largely parked in fixed deposits earning 5.75% returns, suggesting the company is proceeding cautiously with acquisitions and capital expenditure. Three hospital acquisitions completed should provide near-term revenue support.